Details:
TFC-1326 is Sirona’s lead anti-aging compound, will soon enter a clinical trial designed to assess its potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles.
Lead Product(s): TFC-1326
Therapeutic Area: Dermatology Product Name: TFC-1326
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
TFC-1326 1% in formulation is a non-irritant and non-sensitizer, a claim recognized in the industry based on these results and accepted by global regulatory bodies.
Lead Product(s): TFC-1326
Therapeutic Area: Dermatology Product Name: TFC-1326
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
The funding will be used primarily for product development including DispersinB and general working capital. The Company has a portfolio of biotechnologies, intellectual property (81 patents) and products developed by the Company's own biofilm research expertise.
Lead Product(s): DispersinB
Therapeutic Area: Dermatology Product Name: DispersinB
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Marc Edwards
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 06, 2022
Details:
DispersinB® wound gel underwent an extensive pre-clinical testing regimen showing it to be safe, non-toxic and non-irritating, in addition, DispersinB® significantly accelerated healing of both infected and non-infected dermal wound compared to control.
Lead Product(s): DispersinB
Therapeutic Area: Dermatology Product Name: DispersinB
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
PP004 will be used for management of pain and itch in EB, symptoms that, despite a range of current treatment strategies, significantly affect the quality of life in EB patients.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020